A Novo spokesperson said the Danish drugmaker was not ruling out further legal action after announcing new lawsuits against ...

An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.

The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...

Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...

There has been a 27% YoY increase in sales of weight-loss drugs, especially after the launch of Mounjaro and Novo Nordisk's ...

If you’re pregnant or hoping to become pregnant, it’s natural to have questions about your medications. And if you’re taking ...